跳至主要内容
临床试验/NCT06576180
NCT06576180招募中不适用

Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Cognitive Function in Patients With Resectable Head and Neck Squamous Cell Carcinoma: a Prospective Cohort Study

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1 个研究点 分布在 1 个国家目标入组 306 人开始时间: 2024年8月23日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
306
试验地点
1
主要终点
cognitive adverse events, CoAE

研究概览

简要总结

The goal of this observational study is to learn about the Effects of neoadjuvant therapy with carboplatin, paclitaxel combined with anti-PD-1 drugs on cognitive function in patients with resectable head and neck squamous cell carcinoma: a prospective cohort study

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 1: The patient was diagnosed with head and neck squamous cell carcinoma (stage I-IVA), without treatment, and planned to undergo only surgical treatment or surgical treatment + chemotherapy and immunotherapy.
  • 2: Can speak Chinese and have certain reading and writing skills
  • 3: Healthy group: Dental inpatients with non-oral cancer, no history of neurological diseases, and no previous history of malignant tumors

排除标准

  • 1: Brain tumor, brain injury, or stroke at baseline or during follow-up
  • 2: A history of stroke or a medical condition that puts you at high risk for future dementia or recurrence
  • 3: Active mental illness or active narcotic drug use, including using alcohol more than 4 times per day or more than 4 times per week
  • 4: Neurocognitive diseases that affect cognitive function, such as Parkinson's disease or Alzheimer's disease
  • 5: History of drug-associated encephalopathy or brain infection
  • 6: Patients who change their treatment plan during treatment
  • 7: Patients who are currently taking or have taken antidepressants

研究组 & 干预措施

Neoadjuvant therapy+ Surgery group( Group A)

The patient was diagnosed with head and neck squamous cell carcinoma (stage I-IVA), untreated, and planned to undergo surgical treatment + combined chemotherapy and immunotherapy.

干预措施: Carboplatin( neoadjuvant) (Drug)

Neoadjuvant therapy+ Surgery group( Group A)

The patient was diagnosed with head and neck squamous cell carcinoma (stage I-IVA), untreated, and planned to undergo surgical treatment + combined chemotherapy and immunotherapy.

干预措施: Paclitaxel (neoadjuvant) (Drug)

Neoadjuvant therapy+ Surgery group( Group A)

The patient was diagnosed with head and neck squamous cell carcinoma (stage I-IVA), untreated, and planned to undergo surgical treatment + combined chemotherapy and immunotherapy.

干预措施: Anti-PD-1 Drugs (Drug)

Neoadjuvant therapy+ Surgery group( Group A)

The patient was diagnosed with head and neck squamous cell carcinoma (stage I-IVA), untreated, and planned to undergo surgical treatment + combined chemotherapy and immunotherapy.

干预措施: Surgical resection (Procedure)

Direct surgery group (Group B)

The patient was diagnosed with head and neck squamous cell carcinoma (stage I-IVA), untreated, and planned to undergo surgery.

干预措施: Surgical resection (Procedure)

结局指标

主要结局

cognitive adverse events, CoAE

时间窗: Baseline, 9 weeks, 6 months, 12 months

Scores on two or more of the neuropsychological battery tests (NBT) of the HVLT-R, COWA, and TMT are 1.5 SD below the standard mean (or the mean score of an appropriate control group), Or a single test score that is 2.0 SD below the mean can be marked as an objective cognitive adverse event (CoAE).

次要结局

  • Major pathological response rate(Within 30 days after surgery)
  • Montreal Cognitive Assessment, MoCA(The total score is obtained by adding up the scores of each item, and the full score is 30 points. The application results of the original English version of the scale designer show that if the number of years of education is ≤12 years, 1 point is added,)
  • perceived cognitive decline events , PCDE(1/2 standard deviation (SD) of the PCI score in the baseline healthy population is defined as a minimal clinically important difference (MCID), and a change in PCI score that exceeds the MCID in each test will be labeled as PCDE.)
  • complete pathological response rate(Within 30 days after surgery)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Song Fan, MD

Professor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

研究点 (1)

Loading locations...

相似试验